Case Study: Prednisolone

No. Prednisolone has many uses already recorded in the TxGNN knowledge graph. Those are known uses and are excluded. After that check, the MyTxGNN drug page lists 5 predicted new indications, all at evidence level L4.


Quick Overview

Attribute Value
Drug Name Prednisolone
DrugBank ID DB00860
Drug Class Corticosteroid
Predicted New Indications 5
Evidence Level L4

Known Uses Are Not Predictions

Corticosteroids like Prednisolone act on many inflammatory and immune pathways, so the knowledge graph already links them to many diseases. MyTxGNN treats those links as known uses:

  • Indications and contraindications already recorded for the drug in the knowledge graph are excluded
  • Only TxGNN deep learning predictions with a score of at least 0.99 that remain after this check are listed

Predicted New Indications

Predicted Indication
Erythema multiforme
Lymphosarcoma
Disease of orbital region
Leukemia, lymphocytic, susceptibility to
Rheumatic heart disease

See the Prednisolone drug page for evidence and the pharmacist review.


Key Learnings

A prediction that survives the known-use check can still be part of clinical practice. For erythema multiforme, published reviews and case reports already describe systemic corticosteroid treatment, so the prediction mostly confirms existing practice rather than a new discovery.

What This Teaches Us

  1. Exclude known uses first: Counting known uses as predictions inflates the numbers
  2. Check the literature: Use PubMed and clinical trial registries to see whether a prediction is already in use
  3. Consider safety: Long-term corticosteroid use carries risks such as osteoporosis and metabolic effects

Disclaimer
This case study is for educational purposes. Prednisolone should only be used under medical supervision. Drug repurposing predictions require clinical validation before application.

Hak Cipta © 2026 藥提醒科技有限公司 (yao.care). Untuk tujuan penyelidikan sahaja. Bukan nasihat perubatan.

This site uses Just the Docs, a documentation theme for Jekyll.